In this study, using both ER+ and ER− HER2+ breast cancer xenograft models of different genetic background, we demonstrate the great potency of N, either alone or in combination with T, two targeted agents with complementary mechanisms of action, in achieving tumor regression and eradication compared to T and P, either alone or together. The gene discussed is ERBB2; the disease is breast carcinoma.